A global phase II randomized trial comparing oral taxane ModraDoc006/r to intravenous docetaxel in metastatic castration resistant prostate cancer.

Autor: Vaishampayan UN; University of Michigan Ann Arbor, MI, USA., Keessen M; Modra Pharmaceuticals B.V., Amsterdam, Netherlands. Electronic address: mariannekeessen@gmail.com., Dreicer R; University of Virginia, Charlottesville, VA, USA., Heath EI; Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA., Buchler T; Department of Oncology, First Faculty of Medicine, Charles University and Thomayer University Hospital, Prague, Czech Republic., Árkosy PF; Debrecen Institute of Oncology, Debrecen, Hungary., Csöszi T; Hetenyi G Korhaz, Szolnok, Hungary., Wiechno P; Klinika Nowotworów Układu Moczowego Centrum Onkologii, Warsaw, Poland., Kopyltsov E; State Institution of Healthcare, Omsk, Russian Federation., Orlov SV; Pavlov First St. Petersburg State Medical University, Saint Petersburg, Russian Federation., Plekhanov A; Clinic 'Andros' LLC, Saint Petersburg, Russian Federation., Smagina M; Leningrad Regional Oncology Dispensary, Saint Petersburg, Russian Federation., Varlamov S; Altai Regional Cancer Center, Barnaul, Russian Federation., Shore ND; Carolina Urologic Research Center, Myrtle Beach, SC, USA.

Publikováno v: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2024 May; Vol. 202, pp. 114007. Date of Electronic Publication: 2024 Mar 11.